aibioCytomX holders approve 600,000,000 authorized shares and larger equity plans
Tickers CTMX
Stockholders voted on June 17, 2026 to raise authorized common stock from 300,000,000 to 600,000,000 shares. The 8-K does not say what the company plans to do with the extra shares.
Key facts
- Company
- CytomX Therapeutics, Inc. (NASDAQ: CTMX)
- News type
- Listings
- Primary source
- CytomX Therapeutics, Inc. 8-K (2026-06-22)
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported the results of its 2026 Annual Meeting of Stockholders, held on June 17, 2026, in a Form 8-K filed on June 22, 2026. Stockholders approved the charter amendment that doubles the authorized common stock. The company filed the Certificate of Amendment with the Delaware Secretary of State the same day. The filing gives no reason for the larger authorization.
The charter change and the plan increases
The charter amendment drew 178,362,995 votes for, 4,771,689 against and 469,400 abstentions. Stockholders also approved two plan changes that the board adopted in March 2026. The Amended and Restated 2015 Equity Incentive Plan gains 6,500,000 authorized shares, and the Employee Stock Purchase Plan gains 1,000,000. The 2015 plan vote was 147,079,951 for and 1,745,001 against, with 180,010 abstentions and 34,599,122 broker non-votes. The stock purchase plan amendment drew 147,375,197 votes for and 1,468,576 against.
The 8-K puts the record-date count at 217,702,919 shares outstanding on April 20, 2026. Of those, 183,604,084 shares were voted online or by proxy. The company does not say whether it plans to issue any of the newly authorized shares, or when.
Directors, pay and the auditor
Matthew P. Young and Elaine V. Jones Ph.D. were elected Class II directors to serve until the 2029 annual meeting. Young received 146,742,827 votes for, 2,062,471 against and 199,664 abstentions. Jones received 131,377,301 votes for and 17,428,951 against, with 198,710 abstentions. The 17,428,951 votes against Jones are the largest opposition count in the filing.
Stockholders approved the advisory vote on executive pay by 147,127,715 votes for and 1,722,679 against. On how often to hold that vote, 145,004,404 shares chose every year, 2,352,377 chose every three years and 1,298,607 chose every two years. The company says it intends to hold the vote annually. Stockholders ratified Ernst & Young LLP as the auditor for the year ending December 31, 2026, by 182,976,052 votes for and 382,681 against.
The business behind the share count
The annual report, filed on March 16, 2026, calls CytomX a clinical-stage, oncology-focused biopharmaceutical company built on its PROBODY platform. The most advanced program is Varseta-M, an investigational, conditionally activated antibody-drug conjugate aimed at EpCAM and initially focused on colorectal cancer. The report says Varseta-M carries a topoisomerase-1 inhibitor payload licensed from AbbVie, formerly ImmunoGen.
The report also says earlier high-affinity EpCAM antibodies were limited by pancreatitis and liver toxicities and were discontinued. It describes Varseta-M and CX-801 as its two clinical programs, both in Phase 1. It puts existing later-line treatments for metastatic colorectal cancer at median progression-free survival of 2 to 5.6 months and overall survival of about 6 to 11 months. The company plans combination strategies to move Varseta-M into earlier lines of therapy, starting in 2026.
Recent financial position
The annual report shows revenue of $76.2 million for 2025, down from $138.1 million in 2024. Research and development expense was $68.7 million in 2025, down from $83.4 million. The company reported a net loss of $17.4 million for 2025, after net income of $31.9 million in 2024. Cash used in operations was $75.6 million in 2025, against $86.2 million in 2024.
At the end of 2024, the company held $38.1 million in cash and cash equivalents and $62.6 million in short-term investments. The 8-K contains no cash or balance-sheet figures. The 8-K says both plan changes took effect on the date of stockholder approval.